NCT07025811View on ClinicalTrials.gov

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

PHASE4RecruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Dry Eye Disease
Interventions
DRUG

Vevye®

Participants will receive Vevye® (0.1% cyclosporine ophthalmic solution) as per the schedule described in the treatment arm.

DRUG

Xiidra®

Participants will receive Xiidra® (5% lifitegrast ophthalmic solution) as per the schedule described in the treatment arm.

Trial Locations (4)

38119

RECRUITING

Total Eyecare, P.A., Memphis

40206

RECRUITING

Butchertown Clinical Trials, Louisville

01810

RECRUITING

Andover Eye Associates, Andover

24502-4271

RECRUITING

Piedmont Eye Center, Lynchburg

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY